A Phase 1 interventional study of PF-07104091 in Healthy Adults, sponsored by Pfizer. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to learn how the body processes the study medicine PF-07104091.
The study is seeking participants who are:
- Healthy male aged 18 to 65 years of age
Participants in the study will receive 14C-labeled PF-07104091 by mouth after a meal. After 14 days, the participants will receive PF-07104091 by mouth (after a meal) followed by IV fusion (given directly into a vein) of microdose [14C]PF-07104091.
The study will help understand how the body processes study medicine PF-07104091 and how the medicine is changed and removed from the body after you take it. This study will also help to understand how much PF-07104901 is taken up into the blood.
Participants will remain in the study clinic for a maximum of 23 days and will have one follow-up contact.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single oral dose of 14C-labeled PF-07104091 administered under fed conditions.
Drug: PF-07104091
Single oral dose of unlabeled PF-07104091 administered under fed conditions followed by an intravenous (IV) infusion of PF-07104091 containing a microdose of 14C-labeled PF-07104091.
Drug: PF-07104091
Cyclin-dependent kinase-2 inhibitor
Percentage of Total Radiocarbon (14c) excreted in urine
Percentage of 14C excreted in urine following 14C PF-07104091 single dose administration will be determined as: (Total 14C urine/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.
Time frame: From Predose up to 14 days post dose of period 1 and 2
Percentage of Total Radiocarbon (14c) excreted in feces
Percentage of 14C excreted in feces following 14C PF-07104091 single dose administration will be determined as: (Total 14C feces/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.
Time frame: From Predose up to 14 days post dose of period 1 (and if applicable for Period 2)
Percentage of Total Radiocarbon (14c) excreted in vomitus (if applicable)
Percentage of 14C excreted in vomitus (if applicable) following 14C PF-07104091 single dose administration will be determined as: (Total 14C vomitus/ 14C dose administered) \*100 where, 14C dose was administered dose of 14C PF-07104091.
Time frame: From Predose up to 14 days post dose of period 1 only
Cumulative Percent Recovery of Total Radiocarbon (14C)
Percentage recovery of total radioactivity (14C) in urine, feces, and vomitus (If applicable) was determined based on total administered dose.
Time frame: From Predose up to 14 days post dose of period 1 only
Percentage of Metabolite Detected in Plasma After Oral Administration of PF-07104091
The percentage of major metabolites detected in plasma after oral administration of PF-07104091
Time frame: From Predose to 14 days post dose of period 1
Percentage of Metabolite Detected in Urine After Oral Administration of PF-07104091
The percentage of major metabolites detected in urine after oral administration of PF-07104091
Time frame: From Predose to 14 days post dose of period 1
Percentage of Metabolite Detected in Feces After Oral Administration of PF-07104091
The percentage of major metabolites detected in feces after oral administration of PF-07104091
Time frame: From Predose to 14 days post dose of period 1
Oral Absolute Bioavailability
Dose normalized AUCinf (AUCinf\[dn\]) will be calculated as AUCinf/Dose, where AUCinf is the area under the plasma concentration-time profile from time 0 extrapolated to infinite time. Absolute oral bioavailability is defined as the ratio of geometric mean of AUCinf(dn) following orally administered PF-07104091 (i.e., unlabeled PF-07104091) to AUCinf(dn) following intravenously administered \[14C\]PF-07104091 in period 2.
Time frame: From Predose up to 14 days post dose, period 2 only.
Fraction of PF-07104091 Dose Absorbed (Fa)
Fraction of dose absorbed (Fa) will be estimated as the ratio of total or partial radioactivity (dose normalized) excreted into the urine (from time 0 to the time of last measurable concentration) following oral and IV administration of \[14C\]PF-07104091 microtracer dose in Period 1 and 2, respectively.
Time frame: From Predose up to 14 days post dose
Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters
Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame: From baseline up to 35 days after the last dose of study intervention (up to Day 36)
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Aug 2025 to primary completion in Oct 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.